Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $948.57 MXN
Change Today -8.53 / -0.89%
Volume 55.3K
TEVAN On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 4:09 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Open
$962.05
Previous Close
$957.10
Day High
$963.85
Day Low
$948.57
52 Week High
03/31/15 - $963.85
52 Week Low
05/16/14 - $638.00
Market Cap
808.2B
Average Volume 10 Days
7.1K
EPS TTM
--
Shares Outstanding
852.0M
EX-Date
02/17/15
P/E TM
--
Dividend
$1.35
Dividend Yield
1.95%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVAN)

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVAN) Key Developments

Auspex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited - M&A Call

To discuss the merger agreement with Auspex Pharmaceuticals, Inc

Teva Pharmaceutical Industries Limited Announces Pricing of €2 Billion of Senior Notes

Teva Pharmaceutical Industries Limited announced that it priced a €2 billion debt offering, comprised of two tranches: €1.3 billion principal amount of 1.250% senior notes due March 2023 and €700 million principal amount of 1.875% senior notes due March 2027. The notes will be issued by Teva Pharmaceutical Finance Netherlands II B.V., a finance subsidiary of Teva, and will be guaranteed by Teva. The 2023 notes and the 2027 notes are being sold at a price of €990.59 and €995.01 per €1,000 principal amount, respectively. The offering is being made outside the United States to non-U.S. persons in reliance on Regulation S under the U.S. Securities Act of 1933, as amended.

Teva Pharmaceutical Industries Limited Announces Appointment of Timothy R. Wright as Head of Business Development, Strategy and Innovation

Teva Pharmaceutical Industries Limited announced the appointment of Timothy R. Wright Executive Vice President, Business Development, Strategy and Innovation. In this new role, Mr. Wright will be responsible for identifying new sources of innovation and growth that are extensions of Teva's business model. Mr. Wright's appointment will be effective April 13, 2015, and he will report directly to the President and CEO, Erez Vigodman. Timothy R. Wright has almost 30 years of global experience in pharmaceuticals and biotech with a career that has included such roles as Chief Executive Officer, Head of Business Development and Strategy and Head of Global Operations, and has worked extensively in partnership with academia. Most recently, he was the Director of the Drug Discovery and Development Institute at The Ohio State University Comprehensive Cancer Center, where he conceptualized and operationalized the institute, and established external networks that served to accelerate drug development activities and created partnerships among pharmaceutical companies that worked to augment development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $948.57 MXN -8.53

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,918 JPY -50.00
AstraZeneca PLC 4,658 GBp +31.00
Baxter International Inc $68.50 USD -0.26
Eli Lilly & Co $72.65 USD -1.22
Valeant Pharmaceuticals International Inc C$250.21 CAD -6.46
View Industry Companies
 

Industry Analysis

TEVAN

Industry Average

Valuation TEVAN Industry Range
Price/Earnings 17.6x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 19.6x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.